Add to Calendar 5/16/2019 8:00:00 AM 5/16/2019 10:00:00 AM Exploration of Non-traditional Therapeutics: Antibody Drug Conjugates
With over 30 years of R&D history, Antibody-drug Conjugates combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs. Their goal is to transport “deactivated” toxic agents to targeted cancer cells without adversely affecting normal tissues. Once in the tumor cell the cytotoxin’s full cancer killing capability is activated causing rapid cell death. Although it sounds simple these therapies are complex and throughout its history and ongoing research is focused on optimizing the components and the resultant whole in terms of its ability to target the right cells and deliver the most effective knockout punch to cancer cells.
Our distinguished panel of experts will cover:
  • Why ADCs?
  • Latest ADC approaches to speed component selection and testing
  • Modern techniques to ensure stability, targeted delivery, and limited off-target effects
  • Working with FDA to create a joint understanding of how their therapies work and accelerate time to clinical trials
  • Where are we going? The application of ADCs beyond oncology and hematology to other important disease areas
NOTE: This forum will be held at the Ragon Institute Auditorium, 400 Technology Square which is adjacent to the MassBio offices which are at 300 Technology Square.
 Ragon Auditorium, 400 Tech Square, Cambridge, MA 02139
CEO, PercepTx
Barbara brings 25 years of leadership in pharma and biotech to bear on new drug discovery. During her time at Bayer she helped create a new oncology department, and served as project leader for sorafenib, now approved for kidney and liver cancers. Successive leadership positions at Chiron and Millennium consolidated a very broad based experience in advancing large and small molecules to and through clinical trials, with expertise in preclinical pharmacology. Recently at Takeda, Barb’s responsibilities included building a cross country ADC team, evaluating the latest technologies and leading alliance management collaborations to get novel ADCs into the clinic. Barb is currently the CEO of PercepTx, a biotech startup focused on predictive, model driven pre-clinical development of antibody-drug conjugates (ADCs) for cancer therapy. PerepTx takes an engineering-oriented approach that is scalable, capital efficient, and which can create superior clinic-ready ADC therapeutic candidates.